REV-ERB agonist
This protocol is extracted from research article:
A mathematical model of circadian rhythms and dopamine
Theor Biol Med Model, Feb 17, 2021; DOI: 10.1186/s12976-021-00139-w

Experiments using a synthetic REV-ERB agonist suggest that the agonist may induce phase shifts in major clock protein rhythms under 12hr light 12hr dark conditions [11]. We introduce another variable Ag for the amount of REV-ERB agonist over time. In [11], experimentalists reported that the agonist Ag decays exponentially to a negligible amount in 24 hours. Generally, a drug is considered to be negligible after 5 half-lives [33]. Therefore, we take the half-life of Ag to be 4.8 hours, so that Ag undergoes 5 half-lives in 24 hours. Then

In the REV-ERB agonist simulations, the model equations for the repression term Rs and activation term As in dSdt are adjusted so that Ag acts like REV.

We chose a single injection of Ag to be double the REV peak value to exaggerate the effects of the agonist. This value could be adjusted as appropriate.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.